| ARGENX SE EO -,10 |
| Niederlande |
| Gesundheit |
| NL0010832176 / A11602 |
| 1AE (Frankfurt) |
| FRA:1AE, ETR:1AE, 1AE:GR |
| EuroStoxx50 |
| https://www.argenx.com/ |
|
argenx SE is a commercial-stage, global, fully-integrated biopharmaceutical company headquartered in Amsterdam, Netherlands, specializing in the development of differentiated antibody-based therapies for severe autoimmune diseases. The company levera..
>Volltext.. |
| 41794.62 Mio. EUR |
| 38072.01 Mio. EUR |
| 3659.7 Mio. EUR |
| 873.88 Mio. EUR |
| 1131.68 Mio. EUR |
| 18.46 EUR |
| 40.14 Mio. EUR |
| 2971.94 Mio. EUR |
| 726.81 Mio. EUR |
| 3.36 |
| 80.81% |
| 47.1% |
| - |
| - |
| - |
| - |
| ARGENX, ARGEN-X, ARGEN X |
| 07.05.26 |
|